Replies to post #391960 on Innovation Pharmaceuticals Inc (IPIX)

[Here Today]

Head and Neck Cancer never stopped nor did treatments for patients with H&N cancer which in-turn causes OM in patients. So for the life of me, I cannot understand nor believe how Leo let this “Fire” that IPIX had after the FDA meeting concerning the results of the Phase II Clinical Trial and guidance for the Phase III trial just fizzle. He should have hit the Aspire agreement right then and started a trial. At least we could have been financially stable if the P3 showed good results which would have further emboldened IPIX’s position in garnering a better deal from a Big Pharma or legitimate investment banking firm!!! All in my opinion of course.

[MackG]

Because a potential partner insisted it be done. imo

[williamssc]

Good question. Probably the easy answer is back then there was just no call for it. For what I gather Leo paid for this payer analysis so likely insurance reimbursements came up during discussions since B is a new drug for insurance to consider.
My opinion is payer analysis was likely driven by talks with an interested party as part of their current negotiations. If approved B-OM may be considered a new Tier4 drug but since there is no substitute in the fact that OM is a unmet need Insurance would pay for it. It was reported here I think that Leo had a new business development hire. We wait and see.